Cytovia Therapeutics Inc. and Cellectis SA expanded their existing partnership to include new chimeric antigen receptor (CAR) target and development in China by Cytovia’s joint venture firm, Cytolynx Therapeutics Hong Kong Ltd.
Voronoi Inc. licensed global rights to its monopolar spindle1 (MPS1) inhibitor, VRN-08, and a second undisclosed asset to Pyramid Biosciences Inc. in a deal worth up $846 million that preserves Voronoi’s rights to both assets in South Korea.
LONDON – Sosei Heptares is to get $100 million up front in a potential $2.6 billion deal with Neurocrine Biosciences Inc., in which the pair will develop muscarinic receptor agonists in the treatment of schizophrenia, dementia and other neuropsychiatric disorders. San Diego-based Neurocrine is taking rights to a portfolio of small molecules against specific subtypes of the muscarinic receptor family, targeting M1 and M4 alone, plus a dual M1/M4 agonist.
Sotio Biotech AS has licensed Legochem Biosciences Inc.’s technology for five new antibody-drug conjugates (ADC) in a deal that could bring the latter over $1 billion.
Novo Nordisk A/S has taken the plunge and bought its RNA interference (RNAi) technology development partner Dicerna Pharmaceuticals Inc. for around $3.3 billion. Bagsværd, Denmark-based Novo Nordisk has been working with Dicerna, of Lexington, Mass., since 2019 on therapies that selectively silence genes that cause or contribute to disease. RNAi is triggered by double stranded RNA, which causes degradation of a specific RNA target that codes for a rogue disease-causing protein.
Bristol Myers Squibb Co. has completed a $20 million equity investment in Compugen Ltd., part of an ongoing expansion a collaboration between the companies to combine their medicines for the potential benefit of patients with solid tumors.
Roche Holding AG is walking away from a deal with Atea Pharmaceuticals Inc. to co-develop the COVID-19 oral antiviral treatment AT-527 after the mid-October failure of a global phase II study testing the medicine in non-hospitalized adults with mild or moderate disease missed its primary endpoint. Roche’s decision tosses the rights and licenses back to Atea so it can continue its development and commercialization efforts.
Curacle Co. Ltd. is training its sights on more partnerships after nabbing a licensing and collaboration agreement with Théa Open Innovation, a subsidiary of Laboratoires Théa SAS. The deal, for CU06-RE, Curacle’s oral treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD), includes $6 million up front for Curacle and as much as $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales.
Acelyrin Inc. closed a $250 million series B round and, at the same time, unveiled a licensing deal with Affibody AB, involving an interleukin-17A (IL-17A) inhibitor, izokibep, which it is now testing in a pivotal trial in uveitis. Solna, Sweden-based Affibody is getting $25 million up front and could earn up to $280 million more in regulatory and sales-based milestones, as well as tiered royalties, ranging from high single digits to low double digits in percentage terms.
Johnson & Johnson (J&J) will spin off its consumer health division as a stand-alone public company, leaving J&J to focus on its pharmaceutical and medical device businesses.
RSS
